# OnCo record garsorasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/garsorasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "garsorasib" ;
  schema:name "Garsorasib"@en ;
  schema:description "Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation."@en ;
  schema:url <https://onco.cc/drugs/garsorasib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.inventisbio.com/>, <https://doi.org/10.1016/j.jtho.2023.03.015>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule covalent KRAS G12C inhibitor" ;
  onco:approval "China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/inventisbio/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/nct06300177/>, <https://onco.cc/trials/nct04585035/>, <https://onco.cc/trials/nct05379946/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-li-j-thorac-oncol/> .